1. France Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Vetoquinol SA

Vetoquinol SA

79.70
EUR
+1.50
(+1.92%)
837.64MMarket Cap
Mar 25Next Earn
Vetoquinol SA
EURONEXT:VETO
(Euronext)

Recent

price

79.70

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
EUR
25.11
24.27
25.22
25.31
26.58
28.88
29.55
29.7
31.07
33.47
36.15
44.07
45.62
44.73
45.71
45.23
- -
Revenue per Share
1.98
1.94
1.91
1.99
2.17
2.04
2.35
2.94
3.06
2.42
1.63
5.31
4.06
4.7
4.98
4.94
- -
Basic EPS, GAAP
2.37
1.74
2.12
1.74
2.54
2.14
2.5
2.32
2
3.19
-4.5
3.27
3.41
5.95
5.78
4.42
- -
Free Cash Flow per Basic Share
0.29
0.3
0.33
0.35
0.37
0.39
0.41
0.43
0.46
0.48
0.38
0.5
0.8
0.8
0.85
0.9
- -
Dividend per Share
15.51
17.88
19.27
19.94
22.62
24.4
26.69
28.31
30.66
32.65
31.43
37.3
40.95
44.54
48.8
50.87
51.52
Book Value per Share
8.25
10.42
10.84
12.2
12.19
13.89
16.13
18.32
20.22
18.08
9.88
15.16
20.25
25.18
30.28
33.62
34.88
Tangible Book Value per Share
11
12
12
12
12
12
12
12
12
12
12
12
12
12
12
12
12
Basic Weighted Avg Shares
282
284
298
300
315
343
350
352
368
396
427
521
540
529
539
526
- -
Sales/Revenue/Turnover
10.89
11.19
10.67
11.3
11.25
11.62
12.02
12.98
13.14
11.63
13.19
16.47
15.61
14.69
14.15
14.97
- -
Operating Margin (%)
12
12
12
12
13
18
16
12
12
24
46
5
42
35
31
34
- -
Depreciation Expense
22
23
23
24
26
24
28
35
36
29
19
63
48
56
59
57
- -
Net Income, GAAP
26.59
29.17
26.21
26.8
31.56
33.73
29.73
19.31
25.05
30.64
46.76
27.48
34.02
27.75
27.57
28.57
- -
Effective Tax Rate (%)
7.89
7.99
7.57
7.87
8.17
7.05
7.94
9.89
9.85
7.22
4.5
12.06
8.89
10.5
10.88
10.91
- -
Profit Margin (%)
65
94
106
115
138
149
165
173
190
165
68
117
168
224
280
309
330
Working Capital
- -
16
22
11
38
24
15
7
- -
7
8
7
10
10
11
8
7
LT Debt
184
211
228
236
268
289
316
336
363
386
372
441
485
527
576
591
609
Total Equity
11.5
9.18
8.18
8.16
7.28
6.48
7.81
9.83
9.3
6.87
4.1
12.03
9.33
9.53
9.16
8.67
- -
Return on Invested Capital (%)
12.14
10.11
8.85
8.7
8.74
7.59
8.48
10.15
10.11
7.6
4.39
13.28
10.15
10.74
10.42
9.68
- -
Return on Capital (%)
13.13
11.48
10.28
10.17
10.22
8.66
9.19
10.68
10.38
7.63
5.07
15.46
10.37
10.98
10.64
9.83
- -
Return on Common Equity (%)

Capital Structure

EUR

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
ST Debt
5
7
6
LT Borrowings
- -
- -
- -
LT Finance Leases
9
8
7
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
12
12
12
Market Capitalization
877
971
838

Working Capital

EUR

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
Total Current Assets
416
458
471
Cash, Cash Equivalents & STI
182
221
235
Accounts Receivable, Net
89
89
90
Inventories
131
122
133
Total Current Liabilities
134
149
140
Payables & Accruals
- -
- -
- -
ST Debt
5
7
6
Deferred Revenue
- -
- -
- -

Growth Rates

EUR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
7.54%
9.84%
2.69%
Free Cash Flow
-30.83%
-24.4%
-24.65%
Net Income, GAAP
21.31%
44.5%
-2.26%
Sales/Revenue/Turnover
4.57%
4.58%
-2.51%
Total Cash Common Dividend
- -
- -
3.42%

Semi-annual Revenue

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
539
2025
- -
- -
526
2026
- -
- -
- -

Semi-annual Earnings Per Share

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
4.98
2025
- -
- -
4.94
2026
- -
- -
- -

Semi-annual Dividends Per Share

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
0.85
2025
- -
- -
0.9
2026
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Vetoquinol S.A. operates as a global animal health enterprise, engaging in the research, development, production, and distribution of veterinary medications and non-medicinal offerings across Europe, the Americas, Africa, the Middle East, Asia, and Oceania. The company’s extensive product line addresses critical areas such as pain, mobility, and inflammation management; dermatology, hygiene, and overall care; parasitic infections; udder health; various infectious diseases; reproductive health; behavior modification; internal medicine; and cardiology-nephrology solutions. These diverse products are tailored for a wide array of animal species, including companion animals like dogs and cats, as well as livestock such as cattle, pigs, and poultry. Established in 1933 and based in Lure, France, Vetoquinol, a subsidiary of Soparfin SCA, maintains a strategic focus on innovation and its high-growth "Essentials" product portfolio, which continues to drive its performance, with annual sales reaching €539 million in 2024.